Carbamylation of albumin is a cause for discrepancies between albumin assays

Clinica Chimica Acta

Volumn 434, Issue , 2014, Pages 6-10

  Kok, Maarten B ^a   Tegelaers, Frans P W ^a   van Dam, Bastiaan ^b   van Rijn, Jan L M L ^c   van Pelt, Johannes ^a  

^a Location Alkmaar   (Netherlands)

^b Department of Internal Medicine ^*  (Netherlands)

^c Westfriesgasthuis   (Netherlands)

Author keywords

Albumin; BCG; BCP; Bromocresol; Carbamylation; Hemodialysis

Indexed keywords

ALANINE; ALBUMIN; BROMCRESOL PURPLE; BROMOCRESOL GREEN; HOMOCITRULLINE; ISOCYANATE; LYSINE; SERUM ALBUMIN;

ALBUMIN ASSAY; ARTICLE; ASSAY; CARBAMOYLATION; CLINICAL ARTICLE; CONTROLLED STUDY; HEMODIALYSIS PATIENT; HUMAN; IMMUNONEPHELOMETRIC ASSAY; IN VIVO STUDY; INTERMETHOD COMPARISON; KIDNEY FUNCTION; MEASUREMENT; PRIORITY JOURNAL; PROTEIN CONTENT; PURIFICATION; CHEMISTRY; PHOTOMETRY; PROCEDURES; QUALITY CONTROL;

BROMCRESOL GREEN; BROMCRESOL PURPLE; HUMANS; NEPHELOMETRY AND TURBIDIMETRY; QUALITY CONTROL; SERUM ALBUMIN;

EID: 84899828051     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.03.035     Document Type: Article

References (36)

1. Labriola L., Wallemacq P., Gulbis B., Jadoul M. The impact of the assay for measuring albumin on corrected ('adjusted') calcium concentrations. Nephrol Dial Transplant 2009, 24:1834-1838.
2. Lowrie E.G., Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990, 15:458-482.
3. Owen W.F., Lew N.L., Liu Y., Lowrie E.G., Lazarus J.M. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993, 329:1001-1006.
4. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD). Kidney Int Suppl 2009, S1-S130.
5. Clase C.M., St Pierre M.W., Churchill D.N. Conversion between bromcresol green- and bromcresol purple-measured albumin in renal disease. Nephrol Dial Transplant 2001, 16:1925-1929.
6. Jain A., Bhayana S., Vlasschaert M., House A. A formula to predict corrected calcium in haemodialysis patients. Nephrol Dial Transplant 2008, 23:2884-2888.
7. Xu Y., Wang L., Wang J., Liang H., Jiang X. Serum globulins contribute to the discrepancies observed between the bromocresol green and bromocresol purple assays of serum albumin concentration. Br J Biomed Sci 2011, 68:120-125.
8. Parikh C., Yalavarthy R., Gurevich A., Robinson A., Teitelbaum I. Discrepancies in serum albumin measurements vary by dialysis modality. Ren Fail 2003, 25:787-796.
9. Joseph R., Tria L., Mossey R.T., et al. Comparison of methods for measuring albumin in peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 1996, 27:566-572.
10. Wells F.E., Addison G.M., Postlethwaite R.J. Albumin analysis in serum of haemodialysis patients: discrepancies between bromocresol purple, bromocresol green and electroimmunoassay. Ann Clin Biochem 1985, 22:304-309.
11. Speicher C.E., Widish J.R., Gaudot F.J., Hepler B.R. An evaluation of the overestimation of serum albumin by bromcresol green. Am J Clin Pathol 1978, 69:347-350.
12. Blagg C.R., Liedtke R.J., Batjer J.D., et al. Serum albumin concentration-related Health Care Financing Administration quality assurance criterion is method-dependent: revision is necessary. Am J Kidney Dis 1993, 21:138-144.
13. Ueno T., Hirayama S., Ito M., et al. Albumin concentration determined by the modified bromocresol purple method is superior to that by the bromocresol green method for assessing nutritional status in malnourished patients with inflammation. Ann Clin Biochem 2013, 50:576-584.
14. Carfray A., Patel K., Whitaker P., et al. Albumin as an outcome measure in haemodialysis in patients: the effect of variation in assay method. Nephrol Dial Transplant 2000, 15:1819-1822.
15. Pinnell A.E., Northam B.E. New automated dye-binding method for serum albumin determination with bromcresol purple. Clin Chem 1978, 24:80-86.
16. Beyer C., Boekhout M., van Iperen H. Bromcresol purple dye-binding and immunoturbidimetry for albumin measurement in plasma or serum of patients with renal failure. Clin Chem 1994, 40:844-845.
17. Mabuchi H., Nakahashi H. Underestimation of serum albumin by the bromcresol purple method and a major endogenous ligand in uremia. Clin Chim Acta 1987, 167:89-96.
18. Jaisson S., Pietrement C., Gillery P. Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem 2011, 57:1499-1505.
19. Kraus L.M., Kraus A.P. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001, 78:S102-S107.
20. Koeth R.A., Kalantar-Zadeh K., Wang Z., et al. Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol 2013, 24:853-861.
21. Kalim S., Tamez H., Wenger J., et al. Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease. Clin J Am Soc Nephrol 2013, 8:1927-1934.
22. Berg A.H., Drechsler C., Wenger J., et al. Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 2013, 5:175ra29.
23. Gillery P., Jaisson S. Post-translational modification derived products(PTMDPs): toxins in chronic diseases?. Clin Chem Lab Med 2014, 52:33-38.
24. Ito S., Yamamoto D. Identification of two bromocresol purple binding sites on human serum albumin. Clin Chim Acta 2010, 411:1536-1538.
25. Jaisson S., Delevallee-Forte C., Toure F., et al. Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst. FEBS Lett 2007, 581:1509-1513.
26. Waterval W.A., Scheijen J.L., Ortmans-Ploemen M.M., Habets-van der Poel C.D., Bierau J. Quantitative UPLC-MS/MS analysis of underivatised amino acids in body fluids is a reliable tool for the diagnosis and follow-up of patients with inborn errors of metabolism. Clin Chim Acta 2009, 407:36-42.
27. Maguire G.A., Price C.P. Bromcresol purple method for serum albumin gives falsely low values in patients with renal insufficiency. Clin Chim Acta 1986, 155:83-87.
28. Nilsson L., Lundquist P., Kagedal B., Larsson R. Plasma cyanate concentrations in chronic renal failure. Clin Chem 1996, 42:482-483.
29. Calvo R., Carlos R., Erill S. Underestimation of albumin content by bromocresol green, induced by drug displacers and uremia. Int J Clin Pharmacol Ther Toxicol 1985, 23:76-78.
30. Kato A., Takita T., Furuhashi M., et al. Influence of the assay for measuring serum albumin on corrected total calcium in chronic hemodialysis patients. Ther Apher Dial 2011, 15:540-546.
31. Moe S., Drueke T., Cunningham J., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69:1945-1953.
32. Herrmann F.R., Safran C., Levkoff S.E., Minaker K.L. Serum albumin level on admission as a predictor of death, length of stay, and readmission. Arch Intern Med 1992, 152:125-130.
33. Guijarro C., Massy Z.A., Wiederkehr M.R., Ma J.Z., Kasiske B.L. Serum albumin and mortality after renal transplantation. Am J Kidney Dis 1996, 27:117-123.
34. Corti M.C., Guralnik J.M., Salive M.E., Sorkin J.D. Serum albumin level and physical disability as predictors of mortality in older persons. JAMA 1994, 272:1036-1042.
35. Lo S.F., Miller W.G., Doumas B.T. Laboratory performance in albumin and total protein measurement using a commutable specimen: results of a College of American Pathologists study. Arch Pathol Lab Med 2013, 137:912-920.
36. Lieske John C., Bondar O., Miller W.G., et al. A reference system for urinary albumin: current status. Clin Chem Lab Med 2013, 51:981-989.